Benitec Biopharma Ownership
| BNTC Stock | USD 16.11 0.68 4.05% |
Benitec |
Benitec Stock Ownership Analysis
About 46.0% of the company shares are held by institutions such as insurance companies. The book value of Benitec Biopharma was currently reported as 4.68. The company recorded a loss per share of 5.51. Benitec Biopharma last dividend was issued on the 18th of November 2019. The entity had 1:17 split on the 26th of July 2023. Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company was incorporated in 1995 and is headquartered in Hayward, California. Benitec Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people. For more info on Benitec Biopharma Ltd please contact the company at 510 780 0819 or go to https://benitec.com.Benitec Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Benitec Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Benitec Biopharma Ltd backward and forwards among themselves. Benitec Biopharma's institutional investor refers to the entity that pools money to purchase Benitec Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lion Point Capital, Lp | 2024-12-31 | 62 K | Myda Advisors Llc | 2024-12-31 | 50 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 42.4 K | Northern Trust Corp | 2024-12-31 | 38.2 K | 683 Capital Management Llc | 2024-12-31 | 35.8 K | Ameriprise Financial Inc | 2024-12-31 | 35.5 K | Susquehanna International Group, Llp | 2024-12-31 | 24.8 K | Qube Research & Technologies | 2024-12-31 | 20.9 K | State Street Corp | 2024-12-31 | 16.1 K | Suvretta Capital Management, Llc | 2024-12-31 | 9 M | Franklin Resources Inc | 2024-12-31 | 2.9 M |
Benitec Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Benitec Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Benitec Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Benitec Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Benitec Biopharma Outstanding Bonds
Benitec Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Benitec Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Benitec bonds can be classified according to their maturity, which is the date when Benitec Biopharma Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Benitec Biopharma Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.